|
Download
PDF
|
Stakeholder Insight: Psoriasis - Biologics are yet to make topical treatments obsolete
Introduction
Patient perception of disease severity drives treatment-seeking
behavior in psoriasis. New therapeutic options targeting
specific mechanisms are set to reshape severe psoriasis therapy.
However, current biologics have not undermined first-line
topical therapy. In addition to efficacy, reimbursement plays a
crucial role in physicians' prescribing decisions.
Scope
-
Opinion from 180 practicing
dermatologists, each treating at least 40 psoriasis patients per
month
-
Including data from physicians
and opinion leaders across the seven major markets of the US,
Japan, France, Germany, Spain, Italy and the UK
-
Analysis of psoriasis
population attributes, physicians' prescribing decisions,
therapy outcomes and treatment satisfaction
-
Brand analysis of key
pharmaceuticals used in psoriasis, including biologics and
branded topical formulations
Highlights
The low estimated diagnosis rate of 54% reflects a lack of
treatment-seeking by mild sufferers. Despite nearly 10 million
diagnosed patients, the market value of psoriasis is constrained
by reliance on generic and non-prescription treatments in mild
disease.
Biologics' risk-benefit and cost-benefit ratios are coming under
review. Humira (adalimumab) and Stelara (ustekinumab) stand to
benefit from the withdrawal of Raptiva (efalizumab) from the EU
and more stringent labeling in the US. The position of biologics
in moderate to severe psoriasis is up for challenge by payers
attempting to control costs.
Topical treatments are the foundation of therapy, used alone by
at least 82% of mild patients. Phototherapy is a cost-effective
treatment option in psoriasis unresponsive to topical therapy.
Most physicians surveyed recommend phototherapy to up to 30% of
patients, and payers may influence greater use of phototherapy.
Reasons to Purchase
-
Understand how patient behavior
controls the size of the psoriasis market
-
Interpret physicians'
priorities in prescribing personalized psoriasis treatment
regimens
-
Assess the regional dynamics of
therapy choice in psoriasis, dictated by product availability,
regulation and reimbursement
View
Table Of Contents >
|
